Vanzacaftor-tezacaftor-deutivacaftor, a novel therapeutic, once-daily drug, demonstrates noninferiority to elexacaftor-tezacaftor-ivacaftor (the twice-daily, standard-of-care drug) in lung function ...

RIT biomedical engineering researchers identify a protein that can reduce fibrosis and slow disease progression.

Researchers are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and lung fibrosis, conditions that can result in severe damage to the body's tissues.

New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better ...

Please provide your email address to receive an email when new articles are posted on . Few patients with cystic fibrosis have a copy of the 3849+10kb C-to-T splicing mutation. Research is planned to ...

After false starts and incremental gains, scientists crack the problem that made breathing impossible. Will answers come fast ...

Brainomix, a company offering AI-powered imaging tools for stroke and lung fibrosis, announced the completion of an $18 million Series C investment round. The round was co-led by existing investors ...

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and ...

Researchers at the Earlham Institute, the University of Edinburgh and Heriot-Watt University analyzed gut cells to understand ...

A CNIO team finds for the first time in a clinical study that the presence of fibrosis in HER-2 negative breast tumors is associated with an adverse prognosis. The work, published in Clinical Cancer ...